Abstract
Background: RET kinase inhibitors have significant activity in patients with medullary thyroid carcinoma (MTC). Patients and methods: We retrospectively reviewed the electronic medical record for patterns of calcitonin, carcinoembryonic antigen (CEA) and tumor measurement responses in consecutive patients with MTC who received treatment with a RET inhibitor for at least 6 months. Results: Twenty-six patients who received RET kinase inhibitors for at least 6 months were included. All patients experienced an initial decline in calcitonin; 20 (77%) demonstrated later fluctuations in calcitonin, which spiked above baseline levels in 9 individuals (35%). Twenty of the 22 patients (91%) with elevated CEA experienced a decline with treatment, with 11 individuals (50%) later demonstrating transient fluctuations in CEA, including spikes above baseline in 7 patients (32%). Ten of the 26 patients (38%) also demonstrated short-lived fluctuations in RECIST measurements, including changes of over 20% from nadir values. Vacillations in calcitonin, CEA and measurements often occurred repeatedly in individual patients and did not regularly correlate with each other. Conclusions: Repeated transient fluctuations in tumor markers and measurements are a characteristic of patients with MTC receiving treatment with RET inhibitors, and such short-term vacillations may not reflect responsiveness over the long term.
Original language | English (US) |
---|---|
Pages (from-to) | 2256-2261 |
Number of pages | 6 |
Journal | Annals of Oncology |
Volume | 24 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2013 |
Keywords
- Calcitonin
- Carcinoembryonic antigen
- Medullary thyroid carcinoma
- RET inhibition
ASJC Scopus subject areas
- Hematology
- Oncology